Skip to main content

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its board of directors as it prepares to enter clinical development with lead candidate, VMB-100, an RNA-based therapy for the treatment of Stress Urinary Incontinence (SUI).

The appointments come at a significant time of growth and expansion for Versameb. It has recently completed an internal financing round to further strengthen its cash position in preparation to advance its lead candidate, VMB-100, into clinical development in the second half of 2023. In addition, the company is planning to expand its ground-breaking innovative platform with two discovery programs for the treatment of solid tumors with CTA/IND filing expected in 2026.

Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: “The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, VERSagile, with the development of two new discovery programs. Each of the new board members will add knowledge and expertise in all areas of the business as we ramp up for an exciting year of growth and development, executing our company strategy through data readouts of our programs to deliver the promise of RNA therapeutics.”

Share this article

View all news

Sign up to receive our newsletter in your inbox.